Home > > > > Report Detail

Global - Adult Vaccines Market & Company Analysis to 2020

Publisher Name :
Date: 11-May-2015
No. of pages: 232

Adults are as likely as children to die from diseases that they can be immunized. For example, vaccination can prevent about 50% of deaths from pneumococcal disease and 80% of deaths from influenza-related complications in the elderly. Adult vaccines continues to be one of the growing segment for pharmaceutical companies. The adult vaccines market has been forecasted to increase at a compound annual growth rate (CAGR) of around 7% over the next five years. The driving factors for adult vaccines growth are an increasing acceptance of adult vaccines and the public health focus on flu prevention, as well as introductions of new vaccines. The vaccines industry also faces hindrances such as vaccine safety, shortages and delays, vaccine development time line as well as entry barriers for new manufacturers.

Adult Vaccines Market - Disease Wise Analysis

The influenza vaccines are the most popular and accepted vaccination amongst adults. It accounted for maximum share of adult vaccines market in 2014. The vaccinations for hepatitis is the second most popular vaccines in 2014. The HPV/Cervical cancer vaccines and pneumococcal vaccines stands at third and fourth spots respectively in adult vaccines market. While vaccines for zoster shingles and DTP are also gaining ground in adult vaccines market landscape.

Adult Vaccines Market - Company Analysis

Note: Novartis divested its non-influenza vaccine business to GlaxoSmithKline (GSK) and CSL acquires Novartis influenza vaccines business.

In 2010, GSK was the leader in the adult vaccines market but it lost the leadership position to Merck. Sanofi Pasteur stands at the second spot in the adult vaccines market. GSK slipped to third position in the global adult vaccines market in 2014. While Pfizer and Novartis is at the fourth and fifth position respectively in the adult vaccines market landscape.

Adult Vaccines Market - Disease Wise Company Sales Analysis

GSK generates maximum adult vaccines sales from Hepatitis and DTP vaccines, while Sanofi Pasteur remains focused on maintaining its leadership in the influenza market. The cervical cancer and zoster shingles vaccines contributes maximum share of the total Merck adult vaccines sales. Novartis main source of adult vaccines sales revenue is the influenza vaccines.

In 2011, Sanofi Pasteur replaced GSK and became the dominant player in influenza vaccine landscape, while in the cervical cancer market, Merck is at the forefront and is expected to maintain its dominancy over a longer period of time. GSK is the clear leader in hepatitis vaccines market.

Adult Vaccines Market - Regional Distribution

On a regional basis the United States comprises the single largest market for adult vaccines being closely followed by Europe. Japan adult vaccines market share is expected to remain flat during the forecasting period. South America and India are competing closely with each other to get the maximum share of the adult vaccines market pie.

Global - Adult Vaccines Market and Company Analysis to 2020 is a 232 page report with 142 Figures and 8 Tables. This report studies in detail the adult vaccines market disease wise, company wise sales analysis and strategic alliances, mergers and acquisitions along with growth drivers and hindrances for the vaccines market landscape.

The 9 Diseases covered in the report are analyzed from four viewpoints:


  • Adult Vaccines Market (2007 - 2020)

  • Number of Adults Vaccinated (2007 - 2020)

  • Number of Doses (2007 - 2020)

  • Company Sales Share (2010 - 2020)


The 6 Company covered in the report are analyzed from two viewpoints:


  • Disease Wise - Adult Vaccines Sales (2007 - 2020)

  • Strategic Alliances


The 8 Region covered in the report are analyzed from one viewpoint:


  • Adult Vaccines Market (2011 - 2020)


Global Adult Vaccines Market, Number of Adults Vaccinated and Doses - Disease Wise Analysis to 2020 (9 Disease Analysed)


  • Influenza

  • Cervical Cancer

  • Zoster Shingles

  • Pneumococcal

  • Meningococcal

  • MMRV

  • Hepatitis

  • DTP

  • Travel and Miscellaneous


Global Adult Vaccines Market - Company Analysis to 2020 (6 Company Analysed)


  • GlaxoSmithKline

  • Sanofi Pasteur

  • Merck

  • Novartis

  • Pfizer

  • Other Companies


Global Adult Vaccines Market - Regional Distribution to 2020 (8 Region Analysed)


  • United States

  • North America/Caribbean

  • South America

  • Europe

  • Japan

  • India

  • China

  • Rest of the World


Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries And Local Councils and a large number of Paid Databases.

Global - Adult Vaccines Market & Company Analysis to 2020

Table of Contents

1. Executive Summary

2. Global - Adult Vaccines Analysis And Forecast (2007 - 2020)
2.1 Global Adult Vaccines Market and Forecast
2.2 Global Adult Vaccines - Number of Adults Vaccinated and Forecast

3. Global Adult Vaccine Market Share Analysis And Forecast (2010 - 2020)
3.1 Global Adult Vaccines - Disease Wise Adults Vaccinated Share and Forecast
3.2 Global Adult Vaccines - Disease Wise Market Share and Forecast
3.3 Global Adult Vaccines - Company Wise Market Share and Forecast
3.4 Companies Adult Vaccines - Disease Wise Sales Share and Forecast
3.4.1 GlaxoSmithKline (GSK) - Adult Vaccines Sales Share and Forecast
3.4.2 Sanofi Pasteur - Adult Vaccines Sales Share and Forecast
3.4.3 Merck - Adult Vaccines Sales Share and Forecast
3.4.4 Novartis - Adult Vaccines Sales Share and Forecast
3.5 Adult Vaccine Disease Wise Market - Company Share and Forecast
3.5.1 Influenza Adult Vaccines - Company Market Share and Forecast
3.5.2 Cervical Cancer/HPV Adult Vaccines - Company Market Share and Forecast
3.5.3 Hepatitis Adult Vaccines - Company Market Share and Forecast
3.5.4 Pneumococcal Adult Vaccines - Company Market Share and Forecast
3.5.5 Meningococcal Adult Vaccines - Company Market Share and Forecast
3.5.6 DTP (Diphtheria, Tetanus, Pertussis) Adult Vaccines - Company Market Share and Forecast
3.6 Global Adult Vaccines Market - Region Wise Share and Forecast

4. Global Adult Vaccine Market - Disease Wise Analysis
4.1 Influenza - Adult Vaccine Analysis and Forecast (2007 - 2020)
4.1.1 Influenza - Adult Vaccine Market and Forecast
4.1.2 Influenza - Number of Adults Vaccinated and Forecast
4.1.3 Influenza - Number of Vaccines Doses and Forecast
4.2 Cervical Cancer/ HPV - Adult Vaccine Analysis and Forecast (2007 - 2020)
4.2.1 Cervical Cancer/ HPV - Adult Vaccine Market and Forecast
4.2.2 Cervical Cancer/ HPV - Number of Adults Vaccinated and Forecast
4.2.3 Cervical Cancer/ HPV - Number of Vaccines Doses and Forecast
4.3 Zoster Shingles - Adult Vaccine Analysis and Forecast (2007 - 2020)
4.3.1 Zoster Shingles - Adult Vaccine Market and Forecast
4.3.2 Zoster Shingles - Number of Adults Vaccinated and Forecast
4.3.3 Zoster Shingles - Number of Vaccines Doses and Forecast
4.4 Pneumococcal - Adult Vaccine Analysis and Forecast (2010 - 2020)
4.4.1 Pneumococcal - Adult Vaccine Market and Forecast
4.4.2 Pneumococcal - Number of Adults Vaccinated and Forecast
4.4.3 Pneumococcal - Number of Vaccines Doses and Forecast
4.5 Meningococcal - Adult Vaccine Analysis and Forecast (2010 - 2020)
4.5.1 Meningococcal - Adult Vaccine Market and Forecast
4.5.2 Meningococcal - Number of Adults Vaccinated and Forecast
4.5.3 Meningococcal - Number of Vaccines Doses and Forecast
4.6 Measles, Mumps, Rubella and Varicella (MMRV) - Adult Vaccine Analysis and Forecast (2010 - 2020)
4.6.1 Measles, Mumps, Rubella and Varicella (MMRV) - Adult Vaccine Market and Forecast
4.6.2 Measles, Mumps, Rubella and Varicella (MMRV) - Number of Adults Vaccinated and Forecast
4.6.3 Measles, Mumps, Rubella and Varicella (MMRV) - Number of Vaccines Doses and Forecast
4.7 Hepatitis - Adult Vaccine Analysis and Forecast (2007 - 2020)
4.7.1 Hepatitis - Adult Vaccine Market and Forecast
4.7.2 Hepatitis - Number of Adults Vaccinated and Forecast
4.7.3 Hepatitis - Number of Vaccines Doses and Forecast
4.8 Diphtheria, Tetanus, Pertussis (DTP) - Adult Vaccine Analysis and Forecast (2007 - 2020)
4.8.1 Diphtheria, Tetanus, Pertussis (DTP) - Adult Vaccine Market and Forecast
4.8.2 Diphtheria, Tetanus, Pertussis (DTP) - Number of Adults Vaccinated and Forecast
4.8.3 Diphtheria, Tetanus, Pertussis (DTP) - Number of Vaccines Doses and Forecast
4.9 Travel and Miscellaneous - Adult Vaccine Analysis and Forecast (2007 - 2020)

5. Global Adult Vaccine Market - Company Analysis And Strategic Alliances
5.1 GlaxoSmithKline
5.1.1 GlaxoSmithKline (GSK) - Adult Vaccine Sales and Forecast
5.1.2 Strategic Alliances of GlaxoSmithKline (GSK)
5.2 Sanofi Pasteur
5.2.1 Sanofi Pasteur Vaccines Sales and Forecast
5.2.2 Strategic Alliances of Sanofi Pasteur
5.3 Merck
5.3.1 Merck Vaccines Sales and Forecast
5.3.2 Strategic Alliances of Merck
5.4 Novartis
5.4.1 Novartis Vaccines Sales and Forecast
5.4.2 Strategic Alliances of Novartis
5.5 Pfizer
5.5.1 Pfizer Adult Vaccines Sales and Forecast
5.5.2 Strategic Alliances of Pfizer
5.6 Other Companies Sales and Forecast

6. Global Adult Vaccine - Disease Wise Company Sales And Forecast (2007 - 2020)
6.1 GlaxoSmithKline (GSK) - Adult Vaccines Sales and Forecast
6.1.1 GlaxoSmithKline (GSK) - Influenza Adult Vaccines Sales and Forecast
6.1.2 GlaxoSmithKline (GSK) - Cervical Cancer/HPV Adult Vaccines Sales and Forecast
6.1.3 GlaxoSmithKline (GSK) - Hepatitis Adult Vaccines Sales and Forecast
6.1.4 GlaxoSmithKline (GSK) - DTP Adult Vaccines Sales and Forecast
6.2 Sanofi Pasteur - Adult Vaccines Sales and Forecast
6.2.1 Sanofi Pasteur - Influenza Adult Vaccines Sales and Forecast
6.2.2 Sanofi Pasteur - DTP Adult Vaccines Sales and Forecast
6.2.3 Sanofi Pasteur - Meningococcal Adult Vaccines Sales and Forecast
6.3 Merck - Adult Vaccines Sales and Forecast
6.3.1 Merck/CSL - Influenza Adult Vaccines Sales and Forecast
6.3.2 Merck - Cervical Cancer/HPV Adult Vaccines Sales and Forecast
6.3.3 Merck - Zoster Shingles Adult Vaccines Sales and Forecast
6.3.4 Merck - Pneumococcal Adult Vaccines Sales and Forecast
6.3.5 Merck - MMRV Adult Vaccines Sales and Forecast
6.3.6 Merck - Hepatitis Adult Vaccines Sales and Forecast
6.4 Novartis - Adult Vaccines Sales and Forecast
6.4.1 Novartis - Influenza Adult Vaccines Sales and Forecast
6.4.2 Novartis - Meningococcal Adult Vaccines Sales and Forecast
6.5 Pfizer - Adult Vaccines Sales and Forecast
6.5.1 Pfizer - Pneumococcal Adult Vaccines Sales and Forecast

7. Global Adult Vaccine Market - Regional Distribution (2011 - 2020)
7.1 United States - Adult Vaccine Market and Forecast
7.2 North America/Caribbean - Adult Vaccine Market and Forecast
7.3 South America - Adult Vaccine Market and Forecast
7.4 Europe - Adult Vaccine Market and Forecast
7.5 Japan - Adult Vaccine Market and Forecast
7.6 India - Adult Vaccine Market and Forecast
7.7 China - Adult Vaccine Market and Forecast
7.8 Rest of the World (ROW) - Adult Vaccine Market and Forecast

8. Major Vaccine Related Acquisitions (2005-2015)

9. Adult Vaccines Market - Driving Factors
9.1 GAVI Model Fuelling Vaccine Manufacturers
9.1.1 The Partnership Model
9.1.2 The Business Model
9.2 Global Immunization Vision and Strategy (GIVS)
9.3 Growing Vaccine Availability in United States
9.4 The Vaccine Injury Compensation Program
9.5 The Vaccine Safety Data link Project
9.6 Transformation of Vaccine Technologies
9.7 Global Vaccine Action Plan by WHO (2011 - 2020)
9.8 Continuous Focus on Effective Communication Strategies

10. Adult Vaccines Market - Challenges
10.1 Hurdles to Optimal use of Licensed Vaccines
10.1.1 Technical Obstacles
10.1.2 Economic obstacles
10.1.3 Cultural Obstacles
10.2 Shortening the Timeline for Vaccine Development
10.3 Complexity of Vaccine Development and Approval System Thwarts Product Development
10.3.1 Legal Obstacles
10.3.2 General Technical Barriers
10.3.3 Economic Barriers
10.3.4 Regulatory Barriers
10.4 Refusal/Resistance to Vaccination
10.5 Vaccine Adverse Event Reporting System
10.6 Vaccine Shortages and Delays
10.7 Obstacles in Vaccine Research and Development
10.8 Barriers to New Entrants in the Vaccines Market

List of Tables:

Table 3 1: Global - Disease Wise Adults Vaccinated Share (Percent), 2010 - 2014
Table 3 2: Global - Forecast for Disease Wise Adults Vaccinated Share (Percent), 2015 - 2020
Table 3 3: Global Adult Vaccines - Disease Wise Market Share (Percent), 2010 - 2014
Table 3 4: Global Adult Vaccines - Forecast for Disease Wise Market Share (Percent), 2015 - 2020
Table 8 1: Worldwide - Major Vaccine Related Acquisitions, (2005 - 2015)
Table 9 1: Global - Total Future Deaths Averted through Vaccination (Million), 2011 - 2020
Table 9 2: Global Goal-Level Indicators, 2015 & 2020
Table 9 3: Improvement Strategies or Requirements - the Joint Commission and the Project's Collaborating Organizations

List of Figures:

Figure 2 1: Global - Adult Vaccines Market (Million US$), 2007 - 2014
Figure 2 2: Global - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 2 3: Global - Number of Adults Vaccinated (Million), 2007 - 2014
Figure 2 4: Global - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 3 1: Global Adult Vaccines - Company Wise Market Share (Percent), 2010 - 2014
Figure 3 2: Global Adult Vaccines - Forecast for Company Wise Market Share (Percent), 2015 - 2020
Figure 3 3: GlaxoSmithKline (GSK) - Adult Vaccines Sales Share (Percent), 2007 - 2014
Figure 3 4: GlaxoSmithKline (GSK) - Forecast for Adult Vaccines Sales Share (Percent), 2015 - 2020
Figure 3 5: Sanofi Pasteur - Adult Vaccines Sales Share (Percent), 2010 - 2014
Figure 3 6: Sanofi Pasteur - Forecast for Adult Vaccines Sales Share (Percent), 2015 - 2020
Figure 3 7: Merck - Adult Vaccines Sales Share (Percent), 2010 - 2014
Figure 3 8: Merck - Forecast for Adult Vaccines Sales Share (Percent), 2015 - 2020
Figure 3 9: Novartis - Adult Vaccines Sales Share (Percent), 2010 - 2014
Figure 3 10: Novartis - Forecast for Adult Vaccines Sales Share (Percent), 2015 - 2020
Figure 3 11: Influenza Adult Vaccines - Company Market Share (Percent), 2010 - 2014
Figure 3 12: Influenza Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
Figure 3 13: Cervical Cancer/HPV Adult Vaccines - Company Market Share (Percent), 2007 - 2014
Figure 3 14: Cervical Cancer/HPV Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
Figure 3 15: Hepatitis Adult Vaccines - Company Market Share (Percent), 2008 - 2014
Figure 3 16: Hepatitis Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
Figure 3 17: Pneumococcal Adult Vaccines - Company Market Share (Percent), 2010 - 2014
Figure 3 18: Pneumococcal Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
Figure 3 19: Meningococcal Adult Vaccines - Company Market Share (Percent), 2010 - 2014
Figure 3 20: Pneumococcal Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
Figure 3 21: DTP Adult Vaccines - Company Market Share (Percent), 2010 - 2014
Figure 3 22: DTP Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
Figure 3 23: Region Wise - Adult Vaccines Market Share (Percent), 2011 - 2014
Figure 3 24: Region Wise - Forecast for Adult Vaccines Market Share (Percent), 2015 - 2020
Figure 4 1: Influenza - Adult Vaccine Market (Million US$), 2007 - 2014
Figure 4 2: Influenza - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 4 3: Influenza - Number of Adults Vaccinated (Million), 2007 - 2014
Figure 4 4: Influenza - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 4 5: Influenza - Number of Vaccines Doses (Million), 2007 - 2014
Figure 4 6: Influenza - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
Figure 4 7: Cervical Cancer/ HPV - Adult Vaccine Market (Million US$), 2007 - 2014
Figure 4 8: Cervical Cancer/ HPV - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 4 9: Cervical Cancer/ HPV - Number of Adults Vaccinated (Million), 2007 - 2014
Figure 4 10: Cervical Cancer/ HPV - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 4 11: Cervical Cancer/ HPV - Number of Vaccines Doses (Million), 2007 - 2014
Figure 4 12: Cervical Cancer/ HPV - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
Figure 4 13: Zoster Shingles - Adult Vaccine Market (Million US$), 2007 - 2014
Figure 4 14: Zoster Shingles - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 4 15: Zoster Shingles - Number of Adults Vaccinated (Million), 2007 - 2014
Figure 4 16: Zoster Shingles - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 4 17: Zoster Shingles - Number of Vaccines Doses (Million), 2007 - 2014
Figure 4 18: Zoster Shingles - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
Figure 4 19: Pneumococcal - Adult Vaccine Market (Million US$), 2010 - 2014
Figure 4 20: Pneumococcal - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 4 21: Pneumococcal - Number of Adults Vaccinated (Million), 2010 - 2014
Figure 4 22: Pneumococcal - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 4 23: Pneumococcal - Number of Vaccines Doses (Million), 2010 - 2014
Figure 4 24: Pneumococcal - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
Figure 4 25: Meningococcal - Adult Vaccine Market (Million US$), 2010 - 2014
Figure 4 26: Meningococcal - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 4 27: Meningococcal - Number of Adults Vaccinated (Million), 2010 - 2014
Figure 4 28: Meningococcal - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 4 29: Meningococcal - Number of Vaccines Doses (Million), 2010 - 2014
Figure 4 30: Meningococcal - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
Figure 4 31: MMRV - Adult Vaccine Market (Million US$), 2007 - 2014
Figure 4 32: MMRV - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 4 33: MMRV - Number of Adults Vaccinated (Million), 2007 - 2014
Figure 4 34: MMRV - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 4 35: MMRV - Number of Vaccines Doses (Million), 2007 - 2014
Figure 4 36: MMRV - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
Figure 4 37: Hepatitis - Adult Vaccine Market (Million US$), 2007 - 2014
Figure 4 38: Hepatitis - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 4 39: Hepatitis - Number of Adults Vaccinated (Million), 2007 - 2014
Figure 4 40: Influenza - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 4 41: Hepatitis - Number of Vaccines Doses (Million), 2007 - 2014
Figure 4 42: Hepatitis - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
Figure 4 43: DTP - Adult Vaccine Market (Million US$), 2010 - 2014
Figure 4 44: DTP - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 4 45: DTP - Number of Adults Vaccinated (Million), 2010 - 2014
Figure 4 46: DTP - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
Figure 4 47: DTP - Number of Vaccines Doses (Million), 2010 - 2014
Figure 4 48: DTP - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
Figure 4 49: Travel and Miscellaneous - Adult Vaccine Market (Million US$), 2007 - 2014
Figure 4 50: Travel and Miscellaneous - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
Figure 5 1: GlaxoSmithKline (GSK) - Adult Vaccine Sales (Million US$), 2007 - 2014
Figure 5 2: GlaxoSmithKline (GSK) - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
Figure 5 3: Sanofi Pasteur - Adult Vaccine Sales (Million US$), 2010 - 2014
Figure 5 4: Sanofi Pasteur - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
Figure 5 5: Sanofi Pasteur - Pipeline Vaccines candidates (Phase III), February 2015
Figure 5 6: Sanofi Pasteur - Pipeline Vaccines candidates (Phase II), February 2015
Figure 5 7: Sanofi Pasteur - Pipeline Vaccines candidates (Phase I), February 2015
Figure 5 8: Merck - Adult Vaccine Sales (Million US$), 2007 - 2014
Figure 5 9: Merck - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
Figure 5 10: Novartis - Adult Vaccine Sales (Million US$), 2010 - 2014
Figure 5 11: Novartis - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
Figure 5 12: Pfizer - Adult Vaccine Sales (Million US$), 2010 - 2014
Figure 5 13: Pfizer - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
Figure 5 14: Other Companies - Adult Vaccine Sales (Million US$), 2010 - 2014
Figure 5 15: Other Companies - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
Figure 6 1: GlaxoSmithKline (GSK) - Influenza Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 2: GlaxoSmithKline (GSK) - Forecast for Influenza Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 3: GlaxoSmithKline (GSK) - Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 4: GlaxoSmithKline (GSK) - Forecast for Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 5: GlaxoSmithKline (GSK) - Hepatitis Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 6: GlaxoSmithKline (GSK) - Forecast for Hepatitis Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 7: GlaxoSmithKline (GSK) - DTP Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 8: GlaxoSmithKline (GSK) - Forecast for DTP Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 9: Sanofi Pasteur - Influenza Adult Vaccines Sales (Million US$), 2009 - 2014
Figure 6 10: Sanofi Pasteur - Forecast for Influenza Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 11: Sanofi Pasteur - DTP Adult Vaccines Sales (Million US$), 2010 - 2014
Figure 6 12: Sanofi Pasteur - Forecast for DTP Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 13: Sanofi Pasteur - Meningococcal Adult Vaccines Sales (Million US$), 2009 - 2014
Figure 6 14: Sanofi Pasteur - Forecast for Meningococcal Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 15: Merck/CSL - Influenza Adult Vaccines Sales (Million US$), 2010 - 2014
Figure 6 16: Merck/CSL - Forecast for Influenza Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 17: Merck - Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 18: Merck - Forecast for Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 19: Merck - Zoster Shingles Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 20: Merck - Forecast for Zoster Shingles Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 21: Merck - Pneumococcal Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 22: Merck - Forecast for Pneumococcal Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 23: Merck - MMRV Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 24: Merck - Forecast for MMRV Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 25: Merck - Hepatitis Adult Vaccines Sales (Million US$), 2007 - 2014
Figure 6 26: Merck - Forecast for Hepatitis Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 27: Novartis - Influenza Adult Vaccines Sales (Million US$), 2010 - 2014
Figure 6 28: Novartis - Forecast for Influenza Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 29: Novartis - Meningococcal Adult Vaccines Sales (Million US$), 2010 - 2014
Figure 6 30: GSK (Novartis) - Forecast for Meningococcal Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 6 31: Pfizer - Pneumococcal Adult Vaccines Sales (Million US$), 2010 - 2014
Figure 6 32: Novartis - Forecast for Pneumococcal Adult Vaccines Sales (Million US$), 2015 - 2020
Figure 7 1: United States - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 2: United States - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 3: North America/Caribbean - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 4: North America/Caribbean - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 5: South America - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 6: South America - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 7: Europe - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 8: Europe - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 9: Japan - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 10: Japan - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 11: India - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 12: India - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 13: China - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 14: China - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 7 15: ROW - Adult Vaccines Market (Million US$), 2011 - 2014
Figure 7 16: ROW - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
Figure 9 1: US - Number of Retail Clinics offering Vaccination (Number), 2007 - 2012

  • Global Histone Deacetylase (HDAC) Inhibitors Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 87
    The global Histone Deacetylase (HDAC) Inhibitors market was valued at US$ 615.2 million in 2023 and is anticipated to reach US$ 1223.2 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030. North American market for Histone Deacetylase (HDAC) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Histone Deacetylase (HDAC) Inhibitor......
  • Global Esomeprazole Magnesium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 74
    The global Esomeprazole Magnesium market was valued at US$ 5287 million in 2023 and is anticipated to reach US$ 9451.5 million by 2030, witnessing a CAGR of 8.3% during The forecast period 2024-2030. North American market for Esomeprazole Magnesium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Esomeprazole Magnesium is estimated to increase from $ million in 2......
  • Global Combination Therapy Drug Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Combination Therapy Drug market was valued at US$ 105 million in 2023 and is anticipated to reach US$ 166.7 million by 2030, witnessing a CAGR of 4.1% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is......
  • Global Axitinib Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 68
    The global Axitinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The......
  • Global Lyme Disease Vaccine Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 70
    The lyme disease vaccine can reduce lyme disease incidence, reduce symptoms and reduce mortality. Lyme disease is a tick-borne infection of spirochete, a natural disease caused by borrelia burgdorferi. The global Lyme Disease Vaccine market was valued at US$ 257 million in 2023 and is anticipated to reach US$ 763 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at......
  • Global Transdermal Absorption Patch Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Transdermal Absorption Patch market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Transdermal Absorption Patch is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Transdermal Absorption Patch is estimated to increase from $ million i......
  • Global Ketoprofen Patches Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    Ketoprofen patch, indications for The treatment of symptoms caused by The following diseases: rheumatoid arthritis and rheumatoid arthritis The global Ketoprofen Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Ketoprofen Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast per......
  • Global Methyl Salicylate Patches Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 82
    The global Methyl Salicylate Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to......
  • Global Diclofenac Patches Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Diclofenac Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs